Freenome, Inc.
FRNMHealthcareNASDAQDiagnostics & Research · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Freenome, Inc. focuses on Diagnostics & Research services and products. Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. With a market capitalization of $1.37B, it sits in small-cap territory. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer.
Market Cap
$1.37B
Beta
0.45
P/E (TTM)
—
P/E (Fwd)
-5.32
EPS (TTM)
$-2.04
EPS (Fwd)
$-2.40
ROE
—
ROA
—
Cash
$102.0M
Total Debt
$311.5M
Free CF
—
52W Change
19.6%
Annual Financials
Cash vs Debt
Where FRNM stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, FRNM finished 2.03% above its 150-day moving average ($12.32) and 0.40% above its 200-day moving average ($12.52). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FRNM overbought or oversold?
At the October 20, 2026 close, FRNM's RSI(14) was 27.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $102.0M in cash, though total debt stands at $311.5M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Revenue has grown from $2.9M (2024) to $30.4M (2025), reflecting a 955% increase over the period.
With a beta below 0.7, Freenome, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing FRNM.